SignaCor Therapeutics raises €1.1 million to target heart disease
Cardiovascular biotech startup SignaCor Therapeutics has secured a total of €1.1 million in seed funding, including a newly announced €288,000 investment, to accelerate the development of its next-generation therapies for cardiovascular disease. The fresh capital will support preclinical research, expand the company’s scientific team and advance its precision medicine platform.
Focusing on unmet cardiovascular needs
Cardiovascular disease remains the leading cause of death globally, with many patients failing to respond adequately to existing therapies. SignaCor Therapeutics is building a pipeline of targeted treatments aimed at high-risk patient groups who currently lack effective options. By combining advanced biomarker discovery with proprietary drug development tools, the company aims to tailor therapies to specific disease mechanisms rather than relying on one-size-fits-all approaches.
The startup’s platform integrates molecular profiling, data-driven patient stratification and translational research to identify which patients are most likely to benefit from a given therapy. This precision approach is designed to improve outcomes while reducing the burden of trial-and-error prescribing that is common in cardiovascular care.
Use of funds and growth plans
The €1.1 million seed round will be used to deepen preclinical validation of SignaCor’s lead candidates, expand collaborations with academic and clinical partners, and prepare the groundwork for future clinical trials. The company plans to invest in strengthening its core scientific team, including experts in cardiology, pharmacology and computational biology, to accelerate its research pipeline.
Investors are betting that targeted cardiovascular therapeutics will become a major growth area as health systems worldwide seek more effective and cost-efficient ways to manage chronic heart conditions. With this seed funding, SignaCor Therapeutics positions itself as an emerging player in the race to deliver safer, more personalized treatments for patients at risk of heart attack, stroke and heart failure.
As the company advances toward its next milestones, the new financing underscores growing investor confidence in precision medicine as a critical strategy for tackling the global cardiovascular health crisis.